Glenmark surges on launching Nebzmart GFB Smartules and Glenmark Airz FB Smartules
Glenmark Pharmaceuticals is currently trading at Rs. 1874.75, up by 33.70 points or 1.83% from its previous closing of Rs. 1841.05 on the BSE.
The scrip opened at Rs. 1830.25 and has touched a high and low of Rs. 1893.85 and Rs. 1830.25 respectively. So far 12920 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2286.15 on 11-Jul-2025 and a 52 week low of Rs. 1274.70 on 28-Feb-2025.
Last one week high and low of the scrip stood at Rs. 1907.40 and Rs. 1825.00 respectively. The current market cap of the company is Rs. 52990.26 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.38% and 13.97% respectively.
Glenmark Pharmaceuticals has launched Nebzmart GFB Smartules and Glenmark Airz FB Smartules, the world’s first nebulized, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Both products combine three proven medicines - Glycopyrronium, Formoterol, and Budesonide - to reduce airway obstruction, inflammation, and improve lung function and symptom control. As a single, easy-to-use nebulized therapy, it minimizes the burden of multiple medications. This marks a breakthrough as a new standard of care for COPD patients, especially those who struggle with using Metered Dose Inhalers (MDI) or Dry Powder Inhalers (DPI).
In a clinical study conducted in India, this nebulized triple therapy demonstrated rapid improvement in lung function and better control of breathlessness (dyspnea) among patients. The treatment was well tolerated and demonstrated a good safety profile, offering patients a simpler and more effective way to manage COPD.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
.jpg)